Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alivus Life SciencesNSE:ALIVUS +5.87%84 5-Year Yield-on-Cost % is 0.46 as of Aug. 02, 2026, which is 81% below its 10-year median of 2.46. GuruFocus rates NSE:ALIVUS with a GF Score™ of 84/100 and a GF Value™ of ₹1,026.65 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 513 Drug Manufacturers companies, Alivus Life Sciences ranks worse than 85.77% on this metric.
Alivus Life Sciences's yield on cost for the quarter that ended in Jun. 2026 was 0.46.
The historical rank and industry rank for Alivus Life Sciences's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:ALIVUS'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.43 Med: 2.46 Max: 8.04
Current: 0.46
During the past 8 years, Alivus Life Sciences's highest Yield on Cost was 8.04. The lowest was 0.43. And the median was 2.46.
NSE:ALIVUS's 5-Year Yield-on-Cost % is ranked worse than 85.77% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs NSE:ALIVUS: 0.46
Alivus Life Sciences (NSE:ALIVUS) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Alivus Life Sciences 5-Year Yield-on-Cost % Related Terms
NSE:ALIVUS vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's 5-Year Yield-on-Cost % falls into.
Alivus Life Sciences 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Alivus Life Sciences (NSE:ALIVUS) has a 5-Year Yield-on-Cost % of 0.46 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alivus Life Sciences and its competitors. This is 81% below median its historical median of 2.46. Over the past decade, Alivus Life Sciences' 5-Year Yield-on-Cost % has ranged from 0.43 to 8.04. According to the industry distribution chart, Alivus Life Sciences ranks #440 out of 513 companies in the Drug Manufacturers industry, placing it in the top 85.8%.
Is Alivus Life Sciences' 5-Year Yield-on-Cost % too high?
Alivus Life Sciences' current 5-Year Yield-on-Cost % of 0.46 is 81% below median its 10-year median of 2.46. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 8.04. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Alivus Life Sciences' value of 0.46 is 80.2% below this industry median. Based on the distribution chart, Alivus Life Sciences ranks #440 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alivus Life Sciences has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #440 out of 513 companies for 5-Year Yield-on-Cost %. This places Alivus Life Sciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.32. Alivus Life Sciences' value of 0.46 is 80.2% below this benchmark. Historically, Alivus Life Sciences' own 5-Year Yield-on-Cost % has ranged from 0.43 to 8.04 over the past decade. While the company's 10-year median is 2.46 vs. the industry median of 2.32, Alivus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current 5-Year Yield-on-Cost % of 0.46 is 80.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current 5-Year Yield-on-Cost % is 0.46, which is 81% below median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,026.65, compared to a current price of ₹1,160.00 — trading 13% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.46, which is 81% below median its 10-year median of 2.46 and 80.2% below the Drug Manufacturers industry median of 2.32. Alivus Life Sciences' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current 5-Year Yield-on-Cost % is 0.46 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,160.00 is trading 13% above its estimated GF Value™ of ₹1,026.65.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
5-Year Yield-on-Cost %: 0.46 (81% below median its 10-year median of 2.46)
GF Value™: ₹1,026.65 vs. price of ₹1,160.00 (13% above fair value)
Industry Position: 80.2% below the Drug Manufacturers median (#440 of 513)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
84GF Score
Get the complete analysis for NSE:ALIVUS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
